Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MedImmune -- Ignore unavailable to you. Want to Upgrade?

To: BossMan who wrote (128)	8/16/1998 5:39:00 PM
From: JS Ogrady	Read Replies (1) \| Respond to of 416

The Ross pharmaceutical rep mentioned to me that the new Synagis vaccine is going to cost $1000/per immunization and it has to be given monthly. A price like this would indicate the candidates will have to meet very strict criteria for this to be cost effective. This is rather disappointing since it doesn't appear that the vaccine will have any larger target patient population than Respigam did. I think Medi will make a profit off of the new vaccine but it won't be the windfall that I thought it was going to be when it was first announced.